Aspirin Resistance Clinical Trial
Official title:
Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance
The purpose of this study is to determine the incidence of aspirin resistance in the population of vascular surgery patients; and to evaluate the changes in the efficacy of aspirin in the first five postoperative days.
About 15% of the general population shows resistance to the antiplatelet effects of aspirin,
due to genetic polymorphisms and other factors. This resistance is a cause of increased
myocardial infarction and death in patients undergoing percutaneous coronary interventions.
Aspirin resistance can be detected by whole blood impedance aggregometry using the
Multiplate® analyzer. The population of patients undergoing vascular surgery is at
particular risk of suffering myocardial infarction in the perioperative period because of
the high prevalence of risk factors. Most of these patients are treated by aspirin, as a
measure of primary or secondary prevention. In this study we aim to establish baseline
aspirin efficacy, as measured by the Multiplate® analyzer, in this high-risk population and
evaluate the changes in aspirin efficacy over the first five days of the postoperative
period. It is our hypothesis that the state of chronic inflammation, accompanying severe,
generalized atherosclerosis results in a higher incidence of aspirin resistance in this
population. Also, the surgical trauma and postoperative thrombocytosis may reduce the
efficacy of aspirin in the postoperative period, partially explaining the increased
incidence of postoperative myocardial infarction in this population.
In whole blood impedance aggregometry, the electrical impedance of the blood sample is
measured by placing two electrodes in the recipient. After the addition of a platelet
activator, the impedance will increase as platelets accumulate on the electrodes surfaces.
Several activators, testing the patency of different platelet receptors can be used.
In this study, blood will be drawn on the day of surgery, and daily until the fifth
postoperative day. Arachidonic acid, ADP, TRAP-6 and collagen will be used as activators.
The first specifically tests the platelets reactivity to thromboxane A2. Aspirin inhibits
this pathway, and the increase in impedance should therefore be limited in patients treated
by this drug. The three other tests will be performed to evaluate the evolution of overall
platelet reactivity in the postoperative period.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00948987 -
Mechanism Based Resistance to Aspirin
|
Phase 1 | |
Unknown status |
NCT01935193 -
Aspirin Resistance Reversibility in Diabetic Patients
|
Phase 4 | |
Not yet recruiting |
NCT01547039 -
Platelet Reactivity and MES During CEA
|
N/A | |
Completed |
NCT01159639 -
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
|
Phase 4 | |
Completed |
NCT00792272 -
Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients
|
N/A | |
Completed |
NCT00466154 -
The Effect of Serum LDL Lowering on Aspirin Resistance
|
N/A | |
Completed |
NCT01104441 -
Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia
|